We proudly delivered Moderna’s state-of-the-art clinical laboratories as part of the Moderna Innovation and Technology Centre (MITC) at Harwell Campus, Oxfordshire. This landmark facility, the first of its kind for Moderna in the UK, strengthens the nation’s vaccine development and research capabilities, bringing cutting-edge science closer to home.
For Merit, this project was a significant milestone, marking the first deployment of our innovative UltraPOD®+ solution.
This new facility is more than just a building — it’s a vital part of the UK’s ongoing resilience against future pandemics. It empowers researchers with the tools they need to advance groundbreaking mRNA vaccine research, which played a crucial role in combating COVID-19, ensuring the country remains at the forefront of global health innovations.
Key Features
– Delivery of a cutting-edge, two-storey vaccine R&D hub inclusive of clinical biomarker laboratories
– First deployment of Merit’s new UltraPOD®+ product-based solution
– Facility is zero scope 1 carbon enabled, BREEAM Excellent, EPC-A rated.
Key Outcomes
– Delivery of 2,100m2 BSL-2 new containment laboratories
– Delivery of a £25m facility delivered to budget in line with a fixed price contract
– Project duration of 14 months, completed in a third of the time compared to traditional methods of construction.
– A Zero Scope 1 carbon enabled building: the facility meets high environmental standards as a result of Merit’s low-carbon design philosophy